Dementia Drugs Market Size (2024 - 2029)

Dementia Drugs Market Analysis

The Dementia Drugs Market size is estimated at USD 16.44 billion in 2024, and is expected to reach USD 22.21 billion by 2029, growing at a CAGR of 6.20% during the forecast period (2024-2029).

The outbreak of the COVID-19 pandemic had a considerable impact on the dementia drugs market. Certain countries saw significant disruptions in the delivery of pharmacological therapy to dementia patients. According to a study published in Alzheimer's and Dementia in October 2021, 68.6% of monthly sales volume increased compared to the prior year. In March 2020, the month the lockdown began, countries increased consumption volume by 82.3% in 34 European and North American countries. Sales climbed during the pre-pandemic period, with the most obvious spike occurring in March. During the pandemic, use was lower in April and May but increased in June. Hence, COVID-19 significantly impacted the market's growth. However, since the restrictions were lifted, the industry has been recovering well. Over the last two years, the market recovery has been led by the high prevalence of dementia and new product launches.

The factors propelling the market growth are the increasing prevalence of target diseases, the introduction of new and innovative technologies and drugs, and increased government funding and awareness programs for dementia. According to the World Health Organization, in September 2022, around 55 million individuals worldwide had dementia, with more than 60% residing in low- and middle-income counties. As the proportion of the population over the age of 65 years rises in practically every country, this figure is predicted to climb to 78 million in 2030 and 139 million in 2050. Thus, the growing prevalence of dementia worldwide is expected to boost the market's growth.

Increased government funding and awareness programs are the major factors driving the market's growth. For instance, as per a February 2022 update, a new initiative by McGill University's Dementia Education Program was among the 15 projects that would receive funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities. Additionally, in October 2021, the Government of Kerala, India, launched the Dementia-Friendly District program, "Udbodh." This program was undertaken in cooperation with the NeuroScience department at Cochin University of Science and Technology, the Ernakulam district administration, and the Kochi Municipal Corporation. Moreover, in January 2021, LSP, the leading European life sciences investor, launched the LSP Dementia Fund, a fund dedicated to combating neurodegenerative diseases. Such initiatives will boost the awareness of dementia and, ultimately, drugs and treatments, thereby contributing to market growth.

Additionally, in August 2021, the National Institutes of Health (NIH) awarded USD 1.9 million in funding to Tabula Rasa HealthCare Inc. and Hesperos Inc. to investigate drug-induced dementia and develop new models that will drive Alzheimer's research. Such support from public organizations also contributes to the market's growth.

Thus, the market is expected to project growth over the forecast period. However, the high failure rates of drugs at the approval stages are expected to impede market growth over the forecast period.

Dementia Drugs Industry Segmentation

Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent that it interferes with a person's daily life and activities. These functions include memory, language skills, visual perception, problem-solving, self-management, and the ability to focus and pay attention. Alzheimer's is the most common cause of dementia.

The Dementia Drugs Market is Segmented by Indications (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Other Indications), Drug Class (MAO Inhibitors, Glutamate Inhibitors, and Cholinesterase Inhibitors), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.